Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 11/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3642139 | 0.83 | GRM5 (0.62) | GRM5CYP3A4 | |
| SCHEMBL3638810 | 0.80 | GRM5 (0.60) | GRM5CYP3A4 | |
| SCHEMBL3644327 | 0.79 | GRM5 (0.60) | GRM5CYP3A4 | |
| SCHEMBL133741 | 0.79 | TP53 (0.42) | GRM5TP53POLBRXFP1GAA | |
| SCHEMBL3644183 | 0.78 | GRM5 (0.57) | GRM5CYP3A4 | |
| SCHEMBL3644794 | 0.78 | GRM5 (0.57) | GRM5CYP3A4 | |
| SCHEMBL3644596 | 0.78 | GRM5 (0.64) | GRM5CYP3A4POLB | |
| SCHEMBL4264949 | 0.78 | GRM5 (0.56) | GRM5CYP3A4 | |
| SCHEMBL3642555 | 0.78 | GRM5 (0.80) | GRM5CYP3A4 | |
| SCHEMBL513066 | 0.77 | GRM5 (0.43) | GRM5CYP3A4TP53POLBRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042841-A1 | NOVEL HETEROCYCLIC DERIVATIVES AS M-GLU5 ANTAGONISTS | RECORDATI IRELAND LIMITED (IE) | 2009-02-12 | — | — | US | claimed |
| US-8518916-B2 | Heterocyclic derivatives as M-GLU5 antagonists | RECORDATI IRELAND LIMITED (IE) | 2013-08-27 | — | — | US | disclosed |
| US-20090042841-A1 | NOVEL HETEROCYCLIC DERIVATIVES AS M-GLU5 ANTAGONISTS | RECORDATI IRELAND LIMITED (IE) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042841-A1 | NOVEL HETEROCYCLIC DERIVATIVES AS M-GLU5 ANTAGONISTS | GRM5, GRIK5, GRM3 | GRM5 1/4885CYP3A4 2602/4885TP53 4863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.